Penumbra EBITDA 2011-2026 | PEN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Penumbra

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
207 M	33 M	101 M	30.4 M	8.91 M	-26.1 M	55.6 M	36.2 M	4.95 M	947 K	5.93 M	3.76 M	-449 K	3.43 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
207 M	-26.1 M	33.1 M

Quarterly EBITDA Penumbra

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
49 M	41 M	45.4 M	35.5 M	-78.4 M	19.6 M	15.2 M	20.4 M	14.6 M	-	7.98 M	1.9 M	1.68 M	-	19.4 M	10.6 M	16.9 M	-	-10.7 M	-11.6 M	3.57 M	-	18.8 M	16.5 M	13 M	-	-16.4 M	12.2 M	5.44 M	-	3.26 M	94 K	-1.39 M	-	-663 K	-70 K	2.37 M	-	2.68 M	-3.41 M	4.33 M	-	511 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
49 M	-78.4 M	7.63 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Medical devices industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
BioSig Technologies BSGM	-12.7 M	-	37.08 %	$ 85.7 M	USA
GenMark Diagnostics, Inc. GNMK	-3.98 M	-	-	$ 1.77 B	USA
Insulet Corporation PODD	564 M	$ 216.0	-4.21 %	$ 15.2 B	USA
Axonics Modulation Technologies AXNX	-53.2 M	-	-	$ 3.31 B	USA
Aziyo Biologics AZYO	-24.1 M	-	1.37 %	$ 20.5 M	USA
Profound Medical Corp. PROF	-30.3 M	$ 5.82	13.01 %	$ 180 M	Canada
Acutus Medical AFIB	-11.5 M	-	-26.83 %	$ 2.62 M	USA
Allied Healthcare Products AHPI	-815 K	-	3.58 %	$ 2.21 M	USA
Obalon Therapeutics, Inc. OBLN	-9.8 M	-	-5.86 %	$ 30.6 M	USA
Second Sight Medical Products EYES	-24.3 M	-	-0.97 %	$ 54.4 M	USA
Quanterix Corporation QTRX	-110 M	$ 3.96	3.66 %	$ 169 M	USA
AVITA Medical RCEL	-40.2 M	$ 3.99	3.91 %	$ 111 M	Australia
Conformis CFMS	-42.2 M	-	-	$ 16.4 M	USA
Cardiovascular Systems CSII	-32.1 M	-	0.15 %	$ 844 M	USA
IRIDEX Corporation IRIX	-8.91 M	$ 1.33	-1.85 %	$ 21.5 M	USA
Apollo Endosurgery APEN	-30.2 M	-	-	$ 475 M	USA
IRadimed Corporation IRMD	27.3 M	$ 101.78	0.8 %	$ 1.29 B	USA
Avinger AVGR	-16.3 M	-	-20.74 %	$ 369 K	USA
CryoLife, Inc. CRY	23.2 M	-	-4.14 %	$ 702 M	USA
Sintx Technologies SINT	-10.4 M	$ 2.56	-0.39 %	$ 7.1 M	USA
CONMED Corporation CNMD	120 M	$ 37.08	1.42 %	$ 1.15 B	USA
Smith & Nephew plc SNN	1.16 B	-	-	$ 23.8 B	Britain
Soliton, Inc. SOLY	-14.1 M	-	-1.42 %	$ 435 M	USA
Sensus Healthcare SRTS	-9.91 M	$ 4.22	6.57 %	$ 68.9 M	USA
Hancock Jaffe Laboratories, Inc. HJLI	88.4 K	-	-1.98 %	$ 98.3 M	USA
Itamar Medical Ltd. ITMR	-8.53 M	-	0.03 %	$ 1.58 B	Israel
NanoVibronix NAOV	-3.58 M	-	-	$ 1.08 M	USA
Electromed ELMD	10.7 M	$ 24.66	-0.16 %	$ 208 M	USA
Misonix, Inc. MSON	-15.9 M	-	-	$ 462 M	USA
Neovasc NVCN	-31.1 M	-	-	$ 111 M	Canada
Tactile Systems Technology TCMD	35.9 M	$ 26.96	0.37 %	$ 617 M	USA
TELA Bio TELA	-43.6 M	$ 0.69	-9.35 %	$ 15.8 M	USA
Intersect ENT, Inc. XENT	-64.8 M	-	-	$ 955 M	USA
Tandem Diabetes Care TNDM	26 M	$ 24.26	-1.02 %	$ 1.65 B	USA
Cytosorbents Corporation CTSO	-15.2 M	$ 0.67	-3.52 %	$ 36.5 M	USA
Aethlon Medical AEMD	-9 M	$ 2.32	7.41 %	$ 3.62 M	USA
BIOLASE BIOL	-15.1 M	-	-13.19 %	$ 166 K	USA
InspireMD NSPR	426 M	$ 1.77	-1.12 %	$ 114 M	Israel
AdaptHealth Corp. AHCO	473 M	$ 11.39	-0.78 %	$ 1.54 B	USA
Myomo MYO	-13.5 M	$ 0.7	-0.1 %	$ 29.3 M	USA
Nano-X Imaging Ltd. NNOX	-61 M	$ 2.29	-4.58 %	$ 134 M	Israel
Invacare Corporation IVC	-65 M	-	-	$ 24.7 M	USA
EDAP TMS S.A. EDAP	-18 M	$ 3.71	-5.12 %	$ 138 M	France
OrthoPediatrics Corp. KIDS	-18.1 M	$ 16.23	2.01 %	$ 381 M	USA
Outset Medical OM	-62.4 M	$ 3.53	-	$ 53.7 K	USA
Inspire Medical Systems INSP	64.9 M	$ 51.41	-1.27 %	$ 1.51 B	USA
Varex Imaging Corporation VREX	-4.6 M	$ 10.69	0.66 %	$ 443 M	USA